Clinical outcome and ultrasonographic evaluation of treatment using polyglycolic acid-collagen tube for chronic neuropathic pain after peripheral nerve injury

Nerve capping treatment using a bioabsorbable nerve conduit with open or closed end for rat sciatic neuroma

“…This difference could be due to the material properties of the nerve conduits used. The PGA conduit used in the current study was soft and degraded relatively quickly, being completely dissolved by 12 weeks post-implantation [23,24,26,27]. However, the PLA/PCL copolymer nerve conduit had a higher tubular rigidity and longer degradation time (approximately 18 months) than the PGA conduit [17,32,33].…”

“…In the nocapping group, the proximal nerve stump was left without capping. In the capping groups (open-end nerve conduit group and closed-end nerve conduit group), the proximal nerve stump was pulled by 2 mm into the proximal end of the polyglycolic acid (PGA) nerve conduit (Nerbridge; Toyobo Co., Ltd., Osaka, Japan) and sutured with 9-0 nylon sutures in a horizontal mattress pattern on the lumen wall under a microscope (Figure 1 The PGA nerve conduit used in the current study has been commercially available for the treatment of peripheral nerve defects in Japan since 2013, producing clinical outcomes similar to autologous nerve grafting [23][24][25][26]. This PGA nerve conduit was subsequently approved by the US Food and Drug Administration (FDA) in 2016 [27].…”

Nerve-End Capping Treatment with a Polyglycolic Acid Conduit for Rat Sciatic Neuroma: A Preliminary Report

“…The PGA conduit is soft and degrades relatively quickly, being completely dissolved by 12 weeks postimplantation. 25,26,28 Consequently, the axonal extension originating from the transected nerve stump might have been blocked prior to its complete termination by collapse of the PGA conduit, which diminishes the protective effect of the capping. 25,42 On the other hand, in our previous study of nerve-end capping with a nerve conduit consisting of poly L-lactide and polycaprolactone copolymer, the axonal extension could be terminated without collapse of the conduit and the neuropathic pain was significantly reduced.…”

“…25 26 28 Consequently, the axonal extension originating from the transected nerve stump might have been blocked prior to its complete termination by collapse of the PGA conduit, which diminishes the protective effect of the capping. 25 42 On the other hand, in our previous study of nerve-end capping with a nerve conduit consisting of poly L-lactide and polycaprolactone copolymer, the axonal extension could be terminated without collapse of the conduit and the neuropathic pain was significantly reduced. 16 The nerve conduit had a higher tubular rigidity and longer degradation time than the PGA conduit, so that it remained structurally stable at 12 weeks postprocedure.…”

“…[12][13][14][15][16][17][18][19][20][21][22][23] In Japan, a collagen-coated polyglycolic acid (PGA) conduit containing porous collagen fibers within the tube was introduced in 2013; it has been successfully used for the treatment of peripheral nerve defects ever since, producing clinical outcomes similar to autologous nerve grafting. [24][25][26][27] This PGA nerve conduit was also approved for regenerating peripheral nerves by the Food and Drug Administration in the United States in 2016. 28 However, no experimental data are available for using the conduit as a capping device for preventing and treating amputation neuroma.…”